Intrinsic value of CareDx - CDNA

Previous Close

$1.30

  Intrinsic Value

$0.07

stock screener

  Rating & Target

str. sell

-95%

  Value-price divergence*

+1824%

Previous close

$1.30

 
Intrinsic value

$0.07

 
Up/down potential

-95%

 
Rating

str. sell

 
Value-price divergence*

+1824%

*Intrinsic value change (in %) minus stock price change (in %) in the past 12 months.

We calculate the intrinsic value of CDNA stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2016), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.0

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2016(a)
   2017
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  46.43
  57.10
  51.89
  47.20
  42.98
  39.18
  35.76
  32.69
  29.92
  27.43
  25.18
  23.17
  21.35
  19.71
  18.24
  16.92
  15.73
  14.65
  13.69
  12.82
  12.04
  11.33
  10.70
  10.13
  9.62
  9.16
  8.74
  8.37
  8.03
  7.73
  7.45
Revenue, $m
  41
  64
  98
  144
  206
  287
  389
  516
  671
  855
  1,070
  1,318
  1,599
  1,914
  2,264
  2,647
  3,063
  3,512
  3,993
  4,504
  5,047
  5,619
  6,220
  6,850
  7,509
  8,196
  8,913
  9,658
  10,434
  11,240
  12,078
Variable operating expenses, $m
 
  92
  139
  204
  291
  404
  548
  727
  944
  1,202
  1,505
  1,851
  2,247
  2,690
  3,180
  3,718
  4,303
  4,934
  5,609
  6,328
  7,090
  7,893
  8,738
  9,623
  10,549
  11,514
  12,521
  13,568
  14,658
  15,790
  16,967
Fixed operating expenses, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  78
  92
  139
  204
  291
  404
  548
  727
  944
  1,202
  1,505
  1,851
  2,247
  2,690
  3,180
  3,718
  4,303
  4,934
  5,609
  6,328
  7,090
  7,893
  8,738
  9,623
  10,549
  11,514
  12,521
  13,568
  14,658
  15,790
  16,967
Operating income, $m
  -37
  -27
  -41
  -60
  -85
  -117
  -159
  -210
  -273
  -347
  -435
  -534
  -647
  -775
  -916
  -1,072
  -1,240
  -1,422
  -1,616
  -1,824
  -2,043
  -2,275
  -2,518
  -2,773
  -3,040
  -3,318
  -3,608
  -3,910
  -4,224
  -4,551
  -4,890
EBITDA, $m
  -34
  -23
  -35
  -52
  -74
  -103
  -140
  -186
  -242
  -308
  -386
  -475
  -576
  -690
  -816
  -954
  -1,104
  -1,266
  -1,439
  -1,624
  -1,819
  -2,025
  -2,242
  -2,469
  -2,707
  -2,955
  -3,213
  -3,482
  -3,761
  -4,052
  -4,354
Interest expense (income), $m
  1
  1
  2
  4
  6
  10
  14
  20
  27
  35
  45
  57
  71
  86
  103
  122
  143
  166
  191
  217
  245
  275
  306
  339
  374
  410
  448
  487
  528
  570
  615
Earnings before tax, $m
  -41
  -28
  -43
  -63
  -91
  -127
  -173
  -230
  -300
  -383
  -480
  -591
  -718
  -861
  -1,020
  -1,194
  -1,383
  -1,588
  -1,807
  -2,041
  -2,288
  -2,550
  -2,825
  -3,113
  -3,414
  -3,728
  -4,056
  -4,397
  -4,752
  -5,121
  -5,504
Tax expense, $m
  -1
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -39
  -28
  -43
  -63
  -91
  -127
  -173
  -230
  -300
  -383
  -480
  -591
  -718
  -861
  -1,020
  -1,194
  -1,383
  -1,588
  -1,807
  -2,041
  -2,288
  -2,550
  -2,825
  -3,113
  -3,414
  -3,728
  -4,056
  -4,397
  -4,752
  -5,121
  -5,504

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  17
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  77
  100
  153
  225
  321
  447
  607
  805
  1,046
  1,333
  1,669
  2,056
  2,495
  2,987
  3,532
  4,129
  4,778
  5,479
  6,229
  7,027
  7,873
  8,765
  9,703
  10,686
  11,714
  12,787
  13,904
  15,067
  16,277
  17,535
  18,842
Adjusted assets (=assets-cash), $m
  60
  100
  153
  225
  321
  447
  607
  805
  1,046
  1,333
  1,669
  2,056
  2,495
  2,987
  3,532
  4,129
  4,778
  5,479
  6,229
  7,027
  7,873
  8,765
  9,703
  10,686
  11,714
  12,787
  13,904
  15,067
  16,277
  17,535
  18,842
Revenue / Adjusted assets
  0.683
  0.640
  0.641
  0.640
  0.642
  0.642
  0.641
  0.641
  0.641
  0.641
  0.641
  0.641
  0.641
  0.641
  0.641
  0.641
  0.641
  0.641
  0.641
  0.641
  0.641
  0.641
  0.641
  0.641
  0.641
  0.641
  0.641
  0.641
  0.641
  0.641
  0.641
Average production assets, $m
  20
  31
  48
  70
  100
  140
  190
  252
  327
  417
  522
  643
  780
  934
  1,105
  1,292
  1,495
  1,714
  1,948
  2,198
  2,463
  2,742
  3,035
  3,343
  3,664
  4,000
  4,349
  4,713
  5,092
  5,485
  5,894
Working capital, $m
  -14
  -6
  -10
  -14
  -21
  -29
  -39
  -52
  -67
  -85
  -107
  -132
  -160
  -191
  -226
  -265
  -306
  -351
  -399
  -450
  -505
  -562
  -622
  -685
  -751
  -820
  -891
  -966
  -1,043
  -1,124
  -1,208
Total debt, $m
  24
  37
  73
  124
  192
  280
  393
  532
  702
  903
  1,139
  1,411
  1,720
  2,066
  2,449
  2,869
  3,325
  3,817
  4,345
  4,906
  5,501
  6,128
  6,787
  7,478
  8,201
  8,955
  9,741
  10,558
  11,409
  12,293
  13,212
Total liabilities, $m
  57
  71
  107
  158
  226
  314
  427
  566
  736
  937
  1,173
  1,445
  1,754
  2,100
  2,483
  2,903
  3,359
  3,851
  4,379
  4,940
  5,535
  6,162
  6,821
  7,512
  8,235
  8,989
  9,775
  10,592
  11,443
  12,327
  13,246
Total equity, $m
  19
  30
  45
  67
  95
  133
  180
  239
  311
  396
  496
  611
  741
  887
  1,049
  1,226
  1,419
  1,627
  1,850
  2,087
  2,338
  2,603
  2,882
  3,174
  3,479
  3,798
  4,130
  4,475
  4,834
  5,208
  5,596
Total liabilities and equity, $m
  76
  101
  152
  225
  321
  447
  607
  805
  1,047
  1,333
  1,669
  2,056
  2,495
  2,987
  3,532
  4,129
  4,778
  5,478
  6,229
  7,027
  7,873
  8,765
  9,703
  10,686
  11,714
  12,787
  13,905
  15,067
  16,277
  17,535
  18,842
Debt-to-equity ratio
  1.263
  1.230
  1.620
  1.860
  2.010
  2.110
  2.180
  2.220
  2.260
  2.280
  2.300
  2.310
  2.320
  2.330
  2.330
  2.340
  2.340
  2.350
  2.350
  2.350
  2.350
  2.350
  2.360
  2.360
  2.360
  2.360
  2.360
  2.360
  2.360
  2.360
  2.360
Adjusted equity ratio
  0.033
  0.297
  0.297
  0.297
  0.297
  0.297
  0.297
  0.297
  0.297
  0.297
  0.297
  0.297
  0.297
  0.297
  0.297
  0.297
  0.297
  0.297
  0.297
  0.297
  0.297
  0.297
  0.297
  0.297
  0.297
  0.297
  0.297
  0.297
  0.297
  0.297
  0.297

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -39
  -28
  -43
  -63
  -91
  -127
  -173
  -230
  -300
  -383
  -480
  -591
  -718
  -861
  -1,020
  -1,194
  -1,383
  -1,588
  -1,807
  -2,041
  -2,288
  -2,550
  -2,825
  -3,113
  -3,414
  -3,728
  -4,056
  -4,397
  -4,752
  -5,121
  -5,504
Depreciation, amort., depletion, $m
  3
  4
  6
  8
  11
  14
  19
  24
  31
  39
  49
  58
  71
  85
  100
  117
  136
  156
  177
  200
  224
  249
  276
  304
  333
  364
  395
  428
  463
  499
  536
Funds from operations, $m
  -14
  -24
  -37
  -56
  -80
  -113
  -154
  -206
  -268
  -343
  -431
  -532
  -647
  -776
  -919
  -1,077
  -1,248
  -1,432
  -1,630
  -1,841
  -2,065
  -2,300
  -2,549
  -2,809
  -3,081
  -3,365
  -3,661
  -3,969
  -4,289
  -4,622
  -4,969
Change in working capital, $m
  3
  -2
  -3
  -5
  -6
  -8
  -10
  -13
  -15
  -18
  -22
  -25
  -28
  -32
  -35
  -38
  -42
  -45
  -48
  -51
  -54
  -57
  -60
  -63
  -66
  -69
  -72
  -75
  -78
  -81
  -84
Cash from operations, $m
  -17
  -21
  -34
  -51
  -74
  -105
  -144
  -193
  -253
  -325
  -409
  -507
  -619
  -745
  -884
  -1,038
  -1,206
  -1,387
  -1,582
  -1,790
  -2,010
  -2,243
  -2,488
  -2,746
  -3,015
  -3,296
  -3,589
  -3,894
  -4,212
  -4,542
  -4,885
Maintenance CAPEX, $m
  0
  -2
  -3
  -4
  -6
  -9
  -13
  -17
  -23
  -30
  -38
  -47
  -58
  -71
  -85
  -100
  -117
  -136
  -156
  -177
  -200
  -224
  -249
  -276
  -304
  -333
  -364
  -395
  -428
  -463
  -499
New CAPEX, $m
  -1
  -11
  -16
  -23
  -30
  -39
  -50
  -62
  -75
  -90
  -105
  -121
  -137
  -154
  -170
  -187
  -203
  -219
  -235
  -250
  -265
  -279
  -293
  -307
  -321
  -335
  -350
  -364
  -378
  -393
  -409
Cash from investing activities, $m
  -21
  -13
  -19
  -27
  -36
  -48
  -63
  -79
  -98
  -120
  -143
  -168
  -195
  -225
  -255
  -287
  -320
  -355
  -391
  -427
  -465
  -503
  -542
  -583
  -625
  -668
  -714
  -759
  -806
  -856
  -908
Free cash flow, $m
  -38
  -35
  -53
  -78
  -111
  -153
  -207
  -272
  -351
  -444
  -552
  -676
  -815
  -969
  -1,140
  -1,326
  -1,527
  -1,742
  -1,972
  -2,217
  -2,475
  -2,746
  -3,031
  -3,329
  -3,640
  -3,965
  -4,302
  -4,653
  -5,019
  -5,398
  -5,792
Issuance/(repayment) of debt, $m
  17
  26
  37
  51
  68
  88
  112
  139
  169
  202
  236
  272
  309
  346
  383
  420
  457
  492
  527
  561
  595
  627
  659
  691
  723
  754
  786
  818
  851
  884
  919
Issuance/(repurchase) of shares, $m
  8
  39
  58
  85
  120
  164
  220
  289
  371
  468
  579
  705
  848
  1,007
  1,182
  1,371
  1,576
  1,796
  2,030
  2,278
  2,540
  2,815
  3,103
  3,405
  3,719
  4,047
  4,388
  4,743
  5,111
  5,495
  5,893
Cash from financing (excl. dividends), $m  
  25
  65
  95
  136
  188
  252
  332
  428
  540
  670
  815
  977
  1,157
  1,353
  1,565
  1,791
  2,033
  2,288
  2,557
  2,839
  3,135
  3,442
  3,762
  4,096
  4,442
  4,801
  5,174
  5,561
  5,962
  6,379
  6,812
Total cash flow (excl. dividends), $m
  -13
  30
  42
  58
  77
  100
  126
  156
  189
  225
  263
  302
  342
  384
  425
  466
  506
  546
  585
  623
  660
  696
  731
  766
  801
  836
  871
  907
  943
  981
  1,019
Retained Cash Flow (-), $m
  10
  -39
  -58
  -85
  -120
  -164
  -220
  -289
  -371
  -468
  -579
  -705
  -848
  -1,007
  -1,182
  -1,371
  -1,576
  -1,796
  -2,030
  -2,278
  -2,540
  -2,815
  -3,103
  -3,405
  -3,719
  -4,047
  -4,388
  -4,743
  -5,111
  -5,495
  -5,893
Prev. year cash balance distribution, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  -9
  -16
  -27
  -43
  -65
  -94
  -133
  -182
  -243
  -316
  -404
  -506
  -624
  -757
  -906
  -1,070
  -1,250
  -1,445
  -1,655
  -1,880
  -2,119
  -2,372
  -2,638
  -2,918
  -3,211
  -3,517
  -3,836
  -4,168
  -4,514
  -4,873
Discount rate, %
 
  6.90
  7.25
  7.61
  7.99
  8.39
  8.81
  9.25
  9.71
  10.19
  10.70
  11.24
  11.80
  12.39
  13.01
  13.66
  14.34
  15.06
  15.81
  16.61
  17.44
  18.31
  19.22
  20.18
  21.19
  22.25
  23.37
  24.53
  25.76
  27.05
  28.40
PV of cash for distribution, $m
 
  -8
  -14
  -22
  -32
  -43
  -57
  -72
  -87
  -101
  -114
  -125
  -133
  -137
  -137
  -133
  -125
  -115
  -103
  -89
  -76
  -62
  -50
  -38
  -29
  -21
  -15
  -10
  -7
  -4
  -3
Current shareholders' claim on cash, %
  100
  38.9
  15.5
  6.4
  2.7
  1.2
  0.5
  0.2
  0.1
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

CareDx, Inc., a molecular diagnostics company, focuses on the discovery, development, and commercialization of diagnostic surveillance solutions for transplant patients in the United States and internationally. The company’s commercialized testing solution includes the AlloMap heart transplant molecular test (AlloMap), a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function who have a low probability of moderate/severe acute cellular rejection. It is also developing AlloSure, a next-generation sequencing-based test to detect donor-derived cell-free DNA after transplantation. The company markets its AlloMap solution to healthcare providers through its direct sales force that targets transplant centers and their physicians, coordinators, and nurse practitioners. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. CareDx, Inc. was incorporated in 1998 and is headquartered in Brisbane, California.

FINANCIAL RATIOS  of  CareDx (CDNA)

Valuation Ratios
P/E Ratio -0.7
Price to Sales 0.7
Price to Book 1.5
Price to Tangible Book
Price to Cash Flow -1.6
Price to Free Cash Flow -1.5
Growth Rates
Sales Growth Rate 46.4%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 0%
Cap. Spend. - 3 Yr. Gr. Rate NaN%
Financial Strength
Quick Ratio 1
Current Ratio 0
LT Debt to Equity 5.3%
Total Debt to Equity 126.3%
Interest Coverage -40
Management Effectiveness
Return On Assets -57.2%
Ret/ On Assets - 3 Yr. Avg. -26.5%
Return On Total Capital -88.6%
Ret/ On T. Cap. - 3 Yr. Avg. -37.9%
Return On Equity -162.5%
Return On Equity - 3 Yr. Avg. -64.9%
Asset Turnover 0.6
Profitability Ratios
Gross Margin 48.8%
Gross Margin - 3 Yr. Avg. 61.1%
EBITDA Margin -90.2%
EBITDA Margin - 3 Yr. Avg. -43.1%
Operating Margin -90.2%
Oper. Margin - 3 Yr. Avg. -43.1%
Pre-Tax Margin -100%
Pre-Tax Margin - 3 Yr. Avg. -51.2%
Net Profit Margin -95.1%
Net Profit Margin - 3 Yr. Avg. -47.1%
Effective Tax Rate 2.4%
Eff/ Tax Rate - 3 Yr. Avg. 67.5%
Payout Ratio 0%

CDNA stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the CDNA stock intrinsic value calculation we used $41 million for the last fiscal year's total revenue generated by CareDx. The default revenue input number comes from 2016 income statement of CareDx. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our CDNA stock valuation model: a) initial revenue growth rate of 57.1% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 6.9%, whose default value for CDNA is calculated based on our internal credit rating of CareDx, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of CareDx.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of CDNA stock the variable cost ratio is equal to 143.9%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for CDNA stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5% for CareDx.

Corporate tax rate of 27% is the nominal tax rate for CareDx. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the CDNA stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for CDNA are equal to 48.8%.

Life of production assets of 11 years is the average useful life of capital assets used in CareDx operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for CDNA is equal to -10%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $19 million for CareDx - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 19.014 million for CareDx is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of CareDx at the current share price and the inputted number of shares is $0.0 billion.

RELATED COMPANIES Price Int.Val. Rating
FMI Foundation Med 38.00 1.15  str.sell
TMO Thermo Fisher 181.55 75.59  str.sell
GHDX Genomic Health 33.22 3.18  str.sell
MYGN Myriad Genetic 24.32 21.33  hold
OPGN OpGen 0.380 0.02  str.sell
QGEN Qiagen 34.55 16.41  str.sell
GNMK GenMark Diagno 12.26 0.21  str.sell

COMPANY NEWS

▶ ETFs with exposure to CareDx, Inc. : July 10, 2017   [Jul-10-17 02:08PM  Capital Cube]
▶ ETFs with exposure to CareDx, Inc. : June 28, 2017   [Jun-28-17 02:38PM  Capital Cube]
▶ ETFs with exposure to CareDx, Inc. : June 16, 2017   [Jun-16-17 03:31PM  Capital Cube]
▶ CareDx reports 1Q loss   [Jun-09-17 09:04AM  Associated Press]
▶ CareDx Announces Receipt of Expected Letter from Nasdaq   [May-22-17 05:43PM  GlobeNewswire]
▶ CareDx to Present Key AlloSure Validation Data at ATC   [Apr-28-17 04:01PM  GlobeNewswire]
▶ CareDx reports 4Q loss   [Apr-21-17 05:52PM  Associated Press]
▶ CareDx to Present New Data on AlloMap and AlloSure at ISHLT   [Apr-03-17 04:01PM  GlobeNewswire]
▶ CareDx Closes New $25 Million Debt Facility   [04:01PM  GlobeNewswire]
▶ AlloSure Featured in Journal of Applied Laboratory Medicine   [Mar-14-17 04:01PM  GlobeNewswire]
▶ ETFs with exposure to CareDx, Inc. : December 8, 2016   [Dec-08-16 02:24PM  Capital Cube]
▶ CareDx to Participate in Upcoming Investor Conferences   [Nov-08-16 04:01PM  GlobeNewswire]
▶ CareDx to present AlloSure® data at AMP in Charlotte, NC   [Nov-03-16 04:02PM  GlobeNewswire]
▶ CareDx Announces First Commercial Sale of Olerup QTYPE   [Oct-24-16 04:01PM  GlobeNewswire]
▶ CareDx Launches Olerup QTYPE® at ASHI   [Sep-28-16 05:06PM  GlobeNewswire]
▶ CareDx Announces Proposed Public Offering of Common Stock   [Sep-20-16 04:01PM  GlobeNewswire]
▶ CareDx Reports Status of Form 10-Q   [08:00AM  GlobeNewswire]
▶ CareDx Appoints Douglas Miller to Its Board of Directors   [Jul-15-16 04:01PM  GlobeNewswire]
▶ 9 Analyst Stocks Under $10 With Massive Upside Calls   [Jun-18-16 11:25AM  at 24/7 Wall St.]
▶ CareDx to Present at 2016 Jefferies Healthcare Conference   [May-31-16 08:00AM  GlobeNewswire]
Stock chart of CDNA Financial statements of CDNA Annual reports of CDNA
Valuation of Stocks

The paper VALUATION OF STOCKS: The Quest for Intrinsic Value provides a detailed description of our valuation model and discloses the calculation algorithm.

FREE DOWNLOAD
Follow us on:   twitter   twitter   twitter   twitter

VALUATION THEORY       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2017. All rigths reserved.